SEO Article Directory Colorado: Clarinex

Clarinex is a brand name of desloratadine, approved by the FDA in the following formulation(s):

CLARINEX (desloratadine - syrup; oral)

Manufacturer: SCHERING

Approval date: September 1, 2004

Strength(s): 0.5MG/ML ^[RLD]

CLARINEX (desloratadine - tablet, orally disintegrating; oral)

Manufacturer: SCHERING

Approval date: June 26, 2002

Strength(s): 5MG ^[RLD]^[AB]

Manufacturer: SCHERING

Approval date: July 14, 2005

Strength(s): 2.5MG ^[AB]

CLARINEX (desloratadine - tablet; oral)

Manufacturer: SCHERING PLOUGH

Approval date: December 21, 2001

Strength(s): 5MG ^[RLD]^[AB]

Has a generic version of Clarinex been approved?

A generic version of Clarinex has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Clarinex and have been approved by the FDA:

desloratadine tablet, orally disintegrating; oral

Manufacturer: REDDYS

Approval date: July 12, 2010

Strength(s): 2.5MG ^[AB], 5MG ^[AB]

desloratadine tablet; oral

Manufacturer: DR REDDYS LABS LTD

Approval date: March 8, 2011

Strength(s): 5MG ^[AB]

Manufacturer: LUPIN PHARMS

Approval date: October 25, 2010

Strength(s): 5MG ^[AB]

Manufacturer: MYLAN PHARMS INC

Approval date: February 10, 2012

Strength(s): 5MG ^[AB]

Manufacturer: ORCHID HLTHCARE

Approval date: February 19, 2010

Strength(s): 5MG ^[AB]

Manufacturer: PERRIGO R AND D

Approval date: December 22, 2011

Strength(s): 5MG ^[AB]

Manufacturer: SANDOZ

Approval date: December 3, 2010

Strength(s): 5MG ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: November 16, 2010

Strength(s): 5MG ^[AB]

Note: No generic formulation of the following product is available.

desloratadine - syrup; oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Clarinex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Taste masking microparticles for oral dosage forms
Patent 5,607,697
Issued: March 4, 1997
Inventor(s): Alkire; Todd G. & Sanftleben; Ronald A. & Schuehle; Steven S.
Assignee(s): Cima Labs, Incorporated
The present invention relates to a solid dosage form including a new type of taste masking microparticle having an adsorbate of, for example, mannitol, in the core thereof.
Patent expiration dates:
- June 7, 2015
  ✓
  Drug product
- December 7, 2015
  ✓
  Pediatric exclusivity

8-chloro-6,11-dihydro-11- ] (4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
Patent 6,100,274
Issued: August 8, 2000
Inventor(s): Kou; Jim H.
Assignee(s): Schering Corporation
Stable pharmaceutical compositions containing 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cycloheptic[1,2-b ]pyridine("DCL") and a DCL protective amount of a pharmaceutically acceptable basic salt such as calcium dibasic phosphate and an amount of at least one disintegrant, preferably two disintegrates such as microcrystalline cellulose and starch sufficient to provide dissolution of at least about 80% by weight of the pharmaceutical composition in about 45 minutes and suitable for oral administration to treat allergic reactions in mammals such as man are disclosed.
Patent expiration dates:
- July 7, 2019
- July 7, 2019
  ✓
  Drug product
- January 7, 2020
  ✓
  Pediatric exclusivity

Stabilized antihistamine syrup
Patent 6,514,520
Issued: February 4, 2003
Inventor(s): Farah J.; Munayyer & Frank; Guazzo & Elliot I.; Stupak & Imtiaz A.; Chaudry & Joel A.; Sequeira
Assignee(s): Schering Corporation
An antihistaminic syrup is stabilized against degradation of the active ingredient, by the addition of and about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid such as a salt of ethylenediaminetetraacetic acid.
Patent expiration dates:
- June 1, 2018
  ✓
  Drug product
- December 1, 2018
  ✓
  Pediatric exclusivity

Methods for treating urticaria using descarboethoxyloratadine
Patent 7,211,582
Issued: May 1, 2007
Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
Assignee(s): Sepracor Inc.
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Patent expiration dates:
- December 30, 2014
  ✓
  Patent use: TREATMENT OF CHRONIC IDIOPATHIC URTICARIA
- June 30, 2015
  ✓
  Pediatric exclusivity

Compositions of descarboethoxyloratadine
Patent 7,214,683
Issued: May 8, 2007
Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
Assignee(s): Sepracor Inc.
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Patent expiration dates:
- December 30, 2014
  ✓
  Drug product
- June 30, 2015
  ✓
  Pediatric exclusivity

Methods for the treatment of allergic rhinitis
Patent 7,214,684
Issued: May 8, 2007
Inventor(s): Aberg; A. K. Gunnar & McCullough; John R. & Smith; Emil R.
Assignee(s): Sepracor Inc.
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Patent expiration dates:
- December 30, 2014
  ✓
  Patent use: TREATMENT OF ALLERGIC RHINITIS
- June 30, 2015
  ✓
  Pediatric exclusivity

Treating allergic and inflammatory conditions
Patent 7,405,223
Issued: July 29, 2008
Inventor(s): Affrime; Melton B. & Banfield; Christopher R. & Gupta; Samir K. & Padhi; Desmond
Assignee(s): Schering Corporation
A method of treating and/or preventing allergic and inflammatory conditions of the skin or upper and lower airway passages, e.g. seasonal allergic rhinitis, perennial allergic rhinitis, or chronic idopathic urticaria, in a human more 12 years old, by administering an amount of desloratadine, e.g. 2×2.5 mg or 5 mg/day for a time sufficient to produce a geometric mean steady state maximum plasma concentration of desloratadine in the range of about 2.90 ng/mL to about 4.54 ng/mL, or a arithmetic mean steady state maximum plasma concentration of desloratadine in the range of about 3.2 ng/mL to about 5.0 ng/mL is disclosed.
Patent expiration dates:
- July 7, 2019
  ✓
  Patent use: ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA
- January 7, 2020
  ✓
  Pediatric exclusivity

Extended release oral dosage composition
Patent 7,618,649
Issued: November 17, 2009
Inventor(s): Cho; Wing-Kee Philip
Assignee(s): Schering Corporation
A bilayer solid composition comprising (a) an immediate release first layer comprising an anti-allergic effective amount of desloratadine and at least one pharmaceutically acceptable excipient and (b) a sustained release second layer comprising an effective amount of a nasal decongestant, e.g. pseudoephedrine sulfate and a pharmaceutically acceptable sustained release agent wherein the composition contains less than about 2% of desloratadine decomposition products is disclosed. A solid composition comprising an anti-allergic effective amount of desloratadine and at least one, and preferably two pharmaceutically acceptable antioxidants is also disclosed.
Patent expiration dates:
- December 19, 2020
  ✓
  Patent use: A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
  ✓
  Drug product
- June 19, 2021
  ✓
  Pediatric exclusivity

SEO Article Directory Colorado

Friday, September 23, 2016

Clarinex